Fudan University: Carcinoma, Squamous Cell trials

The registry lists 28 Carcinoma, Squamous Cell studies with Fudan University as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 18Phase 3 6No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06814067Phase 2
• AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic TherapyRecruitingNCT06494995Phase 2
• Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCCRecruitingNCT06494943Phase 1/2
• Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 InhibitorRecruitingNCT06190782Phase 3
• A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06152978Phase 2
• A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.RecruitingNCT05760391Not applicable
• Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)RecruitingNCT05281003Phase 2
• Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)RecruitingNCT04519905Not applicable
• Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT05633641
• ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaStatus unknownNCT05426850
• Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)Active, not recruitingNCT04764227Phase 2
• SIB in Upper Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04115618Phase 2
• Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCCCompletedNCT03985046Phase 2
• Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell CarcinomaCompletedNCT03904927Phase 2
• Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT03274011Phase 2
• A Study of SBRT for OligoMetastatic ESCCCompletedNCT03000816Not applicable
• Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT02916511Phase 2
• Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02677597Phase 3
• Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasStatus unknownNCT02665702Phase 2
• A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCCCompletedNCT02647125Phase 2
• A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal CancerCompletedNCT02459457Phase 3
• Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT02384811Phase 2
• Study of S-1 in Combination With Radiotherapy in Esophageal CancerCompletedNCT01831531Phase 2
• A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal CarcinomaCompletedNCT01591135Phase 3
• Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyStatus unknownNCT01402180Phase 2/3
• Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0Status unknownNCT01398449Phase 3
• A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal CancerStatus unknownNCT01391572Phase 2
• Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and NeckStatus unknownNCT01333696Phase 2